This clinical trial is focused on studying the effects of the medication Imatinib in patients who have experienced an acute ischemic stroke. An acute ischemic stroke occurs when a blood clot blocks a blood vessel in the brain, leading to a sudden loss of blood flow and causing brain cells to die. The study aims to determine if taking Imatinib, at a dose of 800 milligrams per day, can improve recovery and functional outcomes for patients three months after the stroke. The treatment is started within eight hours of the stroke symptoms appearing and continues for six days.

Participants in the study will be randomly assigned to receive either the actual medication, Imatinib, or a placebo, which is a substance with no active drug. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results. The medication is administered in two forms: as a film-coated tablet taken orally and as a solution for infusion given intravenously. The trial will monitor changes in the participants’ ability to function independently and their overall neurological health at various points, including 24 hours, seven days, and three months after the stroke.

The primary goal is to see if there is a favorable change in the modified Rankin Scale (mRS) score, which measures the degree of disability or dependence in daily activities, in those treated with Imatinib compared to those who receive the placebo. Secondary outcomes include assessing the level of independence, the occurrence of any brain swelling or bleeding, and the rate of serious and non-serious side effects. The study will also track mortality rates at three months to gather comprehensive data on the safety and effectiveness of Imatinib in treating acute ischemic stroke.